Infectious Disease Research Institute

Sangamo BioSciences appoints H. Stewart Parker to its board of directors

Thursday, June 19, 2014 01:57 PM

Sangamo BioSciences announced the appointment of H. Stewart Parker to the company's board of directors. Parker, who founded and was president and CEO of Targeted Genetics, brings more than 30 years of experience in the biotechnology industry, including 16 years of specific experience in cell and gene therapy.

More... »

Quest Diagnostics

Soligenix, IDRI to develop thermostabilized biodefense vaccines

Wednesday, June 27, 2012 09:44 AM

Soligenix, a development stage biopharmaceutical company, has entered into a collaboration with the Infectious Disease Research Institute (IDRI) of Seattle, Wash., to develop select biodefense vaccines using IDRI's potent and safe synthetic adjuvants in conjunction with Soligenix's proprietary subunit proteins and thermostability platform, ThermoVax. 

More... »


First vaccine for fatal visceral leishmaniasis enters clinical trial

Monday, February 27, 2012 10:08 AM

Seattle-based nonprofit Infectious Disease Research Institute (IDRI) has teamed up with India-based Gennova Biopharmaceuticals to target visceral leishmaniasis (VL), launching a phase I trial of vaccine for the infection disease.

More... »

IDRI supports first phase I human hookworm vaccine trial

Wednesday, February 1, 2012 04:01 PM

The Infectious Disease Research Institute (IDRI) has joined Sabin Vaccine Institute's venture to develop a human hookworm vaccine—which affects 600 million people worldwide—by contributing a proprietary adjuvant as a component. The phase I trial, which began last week in Brazil, aims to reduce the global burden of human hookworm by providing effective long-term protection for those who are most at risk.

More... »

Lilly awards IDRI $4 million in tuberculosis research funding

Tuesday, November 22, 2011 10:55 AM

The Infectious Disease Research Institute (IDRI) has been awarded more than $4 million in additional funding over the next four and a half years by Eli Lilly. The funding will support IDRI’s continued early phase drug discovery research, which focuses on the identification of effective new therapies in the fight against tuberculosis (TB), including multidrug-resistant TB (MDR-TB).

More... »

IDRI joins ADITEC to accelerate human vaccine development

Tuesday, October 18, 2011 02:19 PM

The Infectious Disease Research Institute (IDRI) has joined the Advanced Immunization Technologies (ADITEC) program, a collaborative initiative dedicated to accelerating the development of the next generation of human vaccines. Launched on October 1st, ADITEC will operate with 30 million euros in funding over the course of 5 years contributed by the European Union, with an additional 11 million euros in funding from collaborating organizations.

More... »

IDRI awarded $300k grant for TB vaccine clinical program

Thursday, October 13, 2011 10:25 AM

The Infectious Disease Research Institute (IDRI) has been awarded a two-year $300,000 grant from The Paul G. Allen Family Foundation to support IDRI's launch of a phase I clinical trial of its new tuberculosis vaccine known as ID93/GLA-SE.  The phase I trial will evaluate the safety and immunogenicity of ID93/GLA-SE in a group of healthy volunteers, and is expected to begin in early 2012.

More... »


CWWeekly

May 26

inVentiv Health aims to help sponsors prepare for new E.U. regulations on observational studies

ACRP partners with CRO Analytics to measure investigative sites' views of clinical trial quality

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

Job satisfaction mixed as workload increases
Salaries not keeping pace with rise in work, responsibilities

Gamification moving from early science to patient use
Pharma looking to use games for early diagnosis, recruitment, adherence

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs